CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• CDK4/6 inhibitors are approved for hormone-positive breast cancer.
• Their efficacy in other aggressive cancers remains largely unexplored.
• HER2-positive cancers often develop resistance to existing therapies.

Purpose of the Study:

• To investigate the activity of CDK4/6 inhibitors in HER2-positive cancers.
• To explore the impact of CDK4/6 inhibition on mTOR signaling.
• To determine if CDK4/6 inhibitors can overcome resistance to EGFR/HER2 blockade.

Main Methods:

• Utilized CDK4/6 inhibitors in relevant cancer models.
• Assessed mTOR pathway activity.
• Evaluated the combined effect of CDK4/6 inhibitors and EGFR/HER2 blockade.

Main Results:

• CDK4/6 inhibitors demonstrated unexpected activity in HER2-positive cancer models.
• Inhibition of CDK4/6 led to reduced mTOR signaling.
• Combined treatment re-sensitized HER2-positive cancers to EGFR/HER2 blockade.

Conclusions:

• CDK4/6 inhibitors possess a novel mechanism of action involving mTOR inhibition.
• This activity may offer a new therapeutic strategy for HER2-positive cancers.
• CDK4/6 inhibitors could potentially overcome resistance to EGFR/HER2 targeted therapies.